<DOC>
	<DOCNO>NCT00704730</DOCNO>
	<brief_summary>The purpose research study evaluate progression-free survival ( PFS ) XL184 compare placebo ( inactive substance ) subject unresectable , locally advanced , metastatic medullary thyroid cancer ( MTC ) . Subjects randomize receive XL184 placebo 2:1 ratio . XL184 investigational drug inhibits VEGFR2 , MET RET , kinases implicated tumor formation , growth migration . The Clinical Steering Committee study , comprise study doctor specialize medullary thyroid cancer , provide guidance regard design study . The committee include : Douglas Ball , MD , Barry Nelkin , PhD , Martin Schlumberger , MD Steven Sherman , MD .</brief_summary>
	<brief_title>Efficacy XL184 ( Cabozantinib ) Advanced Medullary Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>The subject histologically confirm diagnosis MTC remove surgery , locally advanced , spread body . The subject least 18 year old . The subject ECOG ( Eastern Cooperative Oncology Group ) performance status ≤ 2 . The subject document worsen disease ( progressive disease ) screening compare previous CT scan MRI image do within 14 month screen . The subject recover clinically significant adverse event ( side effect ) due medication administer prior randomization . The subject adequate organ bone marrow function . Subjects sexually active ( male female ) must agree use medically accept method contraception course study 3 month follow discontinuation study treatment . The subject diagnosis cancer ( unless nonmelanoma skin cancer , early form cervical cancer , another cancer diagnose ≥ 2 year previously ) currently evidence malignancy ( unless nonmelanoma skin cancer early form cervical cancer ) . Female subject childbearing potential must negative pregnancy test screening . The subject receive prior treatment cancer within 4 week randomization ( 6 week nitrosoureas mitomycin C ) . The subject receive radiation ≥ 25 % bone marrow . The subject receive treatment investigational agent ( unapproved therapy ) within 4 week randomization . The subject receive treatment XL184 . The subject brain metastasis spinal cord compression , unless complete radiation therapy ≥ 4 week prior randomization stable without steroid without anticonvulsant treatment ≥ 10 day . The subject history clinically significant episode vomit blood recent history vomit &gt; 2.5 mL ( 1/2 teaspoon ) red blood . The subject serious illness cancer . The subject pregnant breastfeeding . The subject active infection require ongoing treatment . The subject incapable understanding comply protocol unable provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Medullary Thyroid Cancer</keyword>
	<keyword>MTC</keyword>
</DOC>